Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Nov 17.

Published in final edited form as: Antiviral Res. 2014 Jun 16;108:148–155. doi: 10.1016/j.antiviral.2014.06.001

Table 1.

Outcome of treatments for individual sites in the formulation experiment.

Group and treatments	Papillomas induced with 5 ug wtCRPV			Papillomas induced with 5 ug mE8-CRPV

	Growth inhibition^a	Cures^b	Recurrences^c	Growth inhibition^a	Cures^b	Recurrences^c
Group A (1% cidofovir in saline)	1/4	0/4	0/0	1/4	0/4	0/0
Group B (1% cidofovir in 10% DMSO)	2/4	1/4	0/1	3/4	1/4	0/1
Group C (1% cidofovir in carbomer 940)	0/4	2/4	1/2	0/4	4/4	1/4
Group D (1% cidofovir in cremophor)	0/4	4/4	0/4	0/4	4/4	0/4
Group E (saline)	0/2	0/2	0/0	0/2	0/2	0/0
Group F (10% DMSO)	0/2	0/2	0/0	0/2	0/2	0/0
Group G (carbomer 940)	0/2	0/2	0/0	0/2	0/2	0/0
Group H (cremophor)	0/2	0/2	0/0	0/2	0/2	0/0

^a

Papillomas per infected sites.

^b

Cured papillomas per infected sites

^c

Recurrences per cured papillomas